Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | 5 days | Inquiry | |
500 mg | 5 days | Inquiry |
Description | Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2. |
Targets&IC50 | αvβ5 receptor:79 nM, αvβ3 receptor:4.1 nM |
In vitro | 6-Thio-dG induces telomere dysfunction and results in progressive telomere shortening in telomerase-positive human cancer cells and hTERT-expressing human fibroblasts. In tested cancer cells, 6-thio-dG inhibits cell viability with IC50 values between 0.7 and 2.9 μM. [1] |
Molecular Weight | 702.68 |
Formula | C29H41F3N8O9 |
CAS No. | 199807-35-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (132.4 mM)
Ethanol: <1 mg/mL
H2O: 8 mg/mL (11.38 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cilengitide TFA 199807-35-7 Autophagy Cytoskeletal Signaling Integrin Inhibitor EMD121974 EMD 121974 Cilengitide EMD-121974 inhibit inhibitor